The reversal of MGMT promoter methylation, also known as demethylation, is an area of active research. Some demethylating agents, such as 5-azacytidine and decitabine, have been studied for their potential to reactivate silenced genes. However, the clinical applicability and efficacy of these agents in reversing MGMT promoter methylation and improving cancer treatment outcomes remain to be fully established.
